Safrole oxide (
SAFO), a metabolite of naturally occurring hepatocarcinogen
safrole, is implicated in causing
DNA adduct formation. Our previous study first detected the most abundant
SAFO-induced
DNA adduct, N7-(3-benzo[1,3] dioxol-5-yl-2-hydroxypropyl)
guanine (N7γ-SAFO-G), in mouse urine using a well-developed
isotope-dilution high-performance liquid chromatography-electrospray ionization tandem mass spectrometry (ID-HPLC-ESI-MS/MS) method. This study further elucidated the genotoxic mode of action of
SAFO in mice treated with
SAFO 30, 60, 90, or 120 mg/kg for 28 days. The ID-HPLC-ESI-MS/MS method detected N7γ-SAFO-G with excellent sensitivity and specificity in mouse liver and urine of
SAFO-treated mice. Our data provide the first direct evidence of
SAFO-
DNA adduct formation in rodent tissues. N7γ-SAFO-G levels in liver were significantly increased by
SAFO 120 mg/kg compared with
SAFO 30 mg/kg, suggesting rapid spontaneous or enzymatic depurination of N7γ-SAFO-G in tissue
DNA. Urinary N7γ-SAFO-G exhibited a sublinear dose response. Moreover, the micronucleated peripheral reticulocyte frequencies increased dose-dependently and significantly correlated with N7γ-SAFO-G levels in liver (r = 0.8647; p < 0.0001) and urine (r = 0.846; p < 0.0001). Our study suggests that
safrole-mediated genotoxicity may be caused partly by its metabolic activation to
SAFO and that urinary N7γ-SAFO-G may serve as a chemically-specific
cancer risk
biomarker for
safrole exposure.